AlphAIalphai — Financial news for AI agents
thestarphoenix.comAUG 36 min read$LNTH

Curium Announces Definitive Agreement to Merge with Lantheus

Curium and Lantheus (NASDAQ: LNTH) announced a definitive merger agreement. Curium US will acquire all Lantheus shares for $102.50 cash per share at closing plus non-transferable CVRs worth up to $12.00 per share tied to commercial milestones through 2030. Total value up to about $8.0 billion, a 38% premium to 60-day VWAP.

Original reporting
thestarphoenix.com
Published Aug 3, 2026, 12:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 3, 2026, 12:48 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefMergers & acquisitions
Primary signal
$LNTH
Bullish
high confidence
Mentioned
$LNTH
Relevance
10/10
alphai data visualization · based on thestarphoenix.com
Decision brief

The 30-second read

$LNTHBullishHigh
01

Why it matters

For traders, the key new information is the definitive per-share cash consideration, the maximum CVR value and milestone structure, and the stated premiums versus pre-report VWAPs, which together define the investable deal-arb and hedging parameters.

02

Market read

Definitive M&A terms with a large premium and CVR optionality typically drive immediate repricing of the target and create a tradable spread versus the cash offer.

03

What to watch

Deal-spread sensitivity to regulatory timelines and any integration or manufacturing constraints could dominate near-term price action more than the headline premium.

Relevance 10/10Novelty 9/10Timing: today’s definitive merger announcement and cash-plus-CVR terms

Background

Curium and Lantheus are combining radiopharmaceutical manufacturing and theranostics capabilities with Lantheus’ U.S. radiodiagnostics franchise.

Company-level read

Ticker impact

$LNTHBullishHigh confidence
Context

Lantheus agreed to be acquired for $102.50 per share in cash plus up to $12.00 CVRs, valuing the deal at about $8.0B.

Expected impact

Expect LNTH to trade with a premium to the cash offer reflecting deal-spread, CVR pricing, and probability of completion; volatility likely around deal headlines and approvals.

Evidence & confidence

The article discloses definitive consideration, premium vs VWAP, CVR structure tied to 2030 milestones, and unanimous board approval, which are primary inputs for deal-arb and hedging models.

Market effects

Sector

Signals consolidation in nuclear medicine, potentially reshaping competitive positioning across theranostics and U.S. radiodiagnostics.

Regional

U.S.-centric radiodiagnostics footprint is a stated strategic rationale, which may influence U.S. peer deal expectations.

Global

Combined platform targets operations across more than 70 countries, supporting a global scale narrative for radiopharmaceutical supply chains.

Counterpoint

What could challenge this read

CVRs are non-transferable and contingent on commercial milestones through 2030, so the market may discount the upside and focus on cash-offer certainty and closing risk.

Key entities

  • acquirer
    Curium

    Curium US Holdings LLC will acquire Lantheus via a definitive merger agreement.

  • target
    Lantheus

    Lantheus shareholders receive $102.50 per share in cash at closing plus up to $12.00 per share in CVRs tied to milestones through 2030.

  • deal instrument
    Contingent Value Rights (CVRs)

    Non-transferable CVRs providing additional cash payments if specified commercial sales milestones are achieved.

Read at source← All news

Related articles

AUG 6
$LNTHMed

Lantheus (NASDAQ:LNTH) Reports Upbeat Q2 CY2026

Lantheus Holdings (NASDAQ: LNTH) reported Q2 CY2026 revenue of $388.2 million, up 2.7% year on year, ahead of Wall Street expectations. Non-GAAP adjusted EPS was $1.55, 18.9% above consensus. The article also cites adjusted operating margin of 31% and analyst expectations for revenue to decline 3.2% and full-year EPS to fall from $5.95 to $5.55.

financialcontent.com5 min
AUG 6
$LNTHHighAI 10/10

Lantheus Holdings, Inc. (LNTH): Results of Operations and Financial Condition

Lantheus Holdings, Inc. (LNTH) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 lnth-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Lantheus Reports Second Quarter 2026 Financial Results • Worldwide revenue of $388.2 million in the second quarter of 2026 • GAAP fully diluted earnings per share of $1.11, compared to $1.12 in the second quarter of 2025 • Ad

SEC EDGAR 8-K6 min
AUG 4
$LNTHHighAI 9/10

Curium to buy Lantheus in all

Curium US will buy all outstanding shares of Nasdaq-listed Lantheus for $102.50 per share at closing, plus non-transferable CVRs worth up to $12.00 more if 2030 milestones are met, for up to $114.50 total. The offer is a 38% premium to Lantheus’ 60-day VWAP. Board approved unanimously; deal expected to close in H1 2027.

pharmaceutical-business-review.com6 min
AUG 3
$LNTHMed

TD Cowen downgrades Lantheus stock to hold on Curium deal view

TD Cowen downgraded Lantheus Holdings (LNTH) to Hold from Buy and cut its price target to $102.50 from $110.00. Analyst Tara Bancroft said the Curium deal is fair and sees >50% odds of most contingent value milestones, but less optimism on the top PSMA PET tier. The stock trades near $102.03. Separately, the FDA issued a Complete Response Letter for LNTH-2501.

investing.com4 min
AUG 3
$LNTHHighAI 9/10

Lantheus Holdings To Be Acquired By Curium For Up To $8 Bln

Lantheus (LNTH) said it agreed to be acquired by Curium, backed by CapVest, for up to $8 billion. Curium US will buy all LNTH shares for $102.50 cash plus non-transferable Contingent Value Rights up to $12 per share tied to milestones through 2030. Total up to $114.50 per share, a 38% premium. Deal expected to close in 1H 2027.

rttnews.com4 min